ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DMA Diamedica Therapeutics

4.63
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Diamedica Therapeutics TSXV:DMA TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.63 4.57 5.00 0 01:00:00

DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders

06/11/2018 10:00pm

GlobeNewswire Inc.


DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more DiaMedica Inc. Charts.

DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual General and Special Shareholders Meeting held on November 6, 2018. A total of 51.4% of the issued and outstanding common shares of the Company were present either in person or by proxy at the meeting.

The following five nominees proposed by the Company were elected as Directors of DiaMedica to serve until the Company’s next Annual General Meeting of Shareholders. The vote results were as follows:

DIRECTORVOTES CAST FOR% OF VOTES CAST FORWITHHELD% WITHHELD
Dr. Michael Giuffre56,984,55299.87%71,7500.13%
James Parsons57,055,102100%1,2000%
Rick Pauls57,038,25299.97%18,0500.03%
Richard Pilnik57,045,10299.98%11,2000.02%
Zhenyu "Jerry" Xiao57,055,102100%1,2000%

DiaMedica shareholders also approved all ballot resolutions, with a minimum of 95.5% of votes cast in favor of each resolution, placed before the meeting and as outlined in the Management Information Circular dated September 30, 2018. The Company’s Management Information Circular is available at www.sedar.com for more details on the matters covered at the meeting. Final voting results on all matters voted on at the meeting will also be filed on SEDAR.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s common shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and quoted on the OTCQB marketplace under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.

For further information, please contact:

Paul Papi Vice President of Business Development DiaMedica Therapeutics Inc. Two Carlson Parkway, Suite 260 Minneapolis, MN Phone: (617) 899-5941 info@diamedica.com

Tweet this!

 

1 Year DiaMedica Inc. Chart

1 Year DiaMedica Inc. Chart

1 Month DiaMedica Inc. Chart

1 Month DiaMedica Inc. Chart

Your Recent History

Delayed Upgrade Clock